Skip to main content
Longevity Stack
Peptides/Regenerative

BPC-157

Grade B

Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.

Category
Regenerative
Evidence grade
B
Route
Subcutaneous or oral (gut-localized)
Half-life
~4 hours (subcutaneous)
Typical dose
250–500 mcg
Frequency
1–2× daily
Cycle length
4–6 weeks on, 4 weeks off
Best timing
Near site of injury or AM/PM fasted
Why BPC-157 matters

Tissue repair, gut integrity. Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.

  • Accelerated soft-tissue recovery in preclinical models
  • Gut barrier integrity and ulcer protection
  • Potential nervous system neuroprotection
Typical dose
250–500 mcg
Frequency
1–2× daily
Route
Subcutaneous or oral (gut-localized)
Evidence
Grade B

Mechanism of Action

Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.

Typical Protocol

Dose
250–500 mcg
Frequency
1–2× daily
Duration
4–6 weeks on, 4 weeks off
Timing
Near site of injury or AM/PM fasted
Route
Subcutaneous or oral (gut-localized)
Half-life
~4 hours (subcutaneous)

Educational reference only — not medical advice.

Pharmacokinetics & Dosing Rationale

BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~4 hours (subcutaneous). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.

How to Administer

  1. Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily.
  2. Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible.
  3. Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating.
  4. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Reconstitution & Injection Technique

  1. Reconstitute lyophilised powder with bacteriostatic water (0.9% benzyl alcohol) — sterile water is acceptable but shortens shelf life to ~72 hours.
  2. Typical dilution: add 2 mL of bacteriostatic water to a 5 mg vial → 2.5 mg/mL; a 10-unit insulin syringe mark = 0.25 mg.
  3. Inject the diluent slowly against the vial wall — never onto the powder — and gently swirl. Do not shake; peptides denature under shear.
  4. Once reconstituted, store upright in the refrigerator (2–8 °C) and use within 30 days.
  5. Draw the dose with an insulin syringe (29–31G, 8 mm), swab the site with alcohol, pinch subcutaneous tissue on the abdomen or thigh, inject at 90°.

Sterile technique is not optional. Use a fresh needle for every injection.

Cycling & Stacking Strategy

  • Standard protocol: 250–500 mcg, 1–2× daily, for 4–6 weeks on, 4 weeks off.
  • Ramp up: start at the lower end of the dose range for the first 7–10 days to gauge tolerance and side effects before titrating.
  • Break periods let receptor sensitivity and endogenous feedback loops normalise — running back-to-back cycles without a wash-out erodes the effect.
  • Common stack: TB-500, Collagen peptides, Vitamin C. Introduce one compound at a time so you can attribute effect and side effect.

Who This Is For

Good candidates
  • Adults with a specific, measurable goal aligned to tissue repair, gut integrity.
  • People who already have baseline bloods, a training routine and a sleep protocol in place.
  • Users who can commit to a full cycle, log the protocol, and re-test biomarkers to evaluate response.
  • Anyone working with a clinician willing to supervise off-label or investigational protocols.
Not appropriate for
  • Anyone with active or recent malignancy, or a strong family cancer history where mechanism is angiogenic or growth-promoting.
  • Pregnant or breastfeeding women — human safety data is absent for almost all research peptides.
  • Adolescents and anyone under 21 whose endocrine axis is still developing.
  • People unwilling to run baseline and post-cycle bloods.
  • Specific contraindications for BPC-157: Active malignancy (theoretical angiogenic concern); Pregnancy and lactation.

What to Monitor

Injury / pain score (VAS 0–10)Log weekly at rest and after loading — the primary outcome you care about.
Range of motion / functional testRepeat the same test weekly to see objective recovery.
Skin, mole & lymph checkAngiogenic peptides warrant a baseline dermatology check.
Take it with you

Download a printable version of this checklist to log baseline, weekly and post-cycle results.

Reported Benefits

  • Accelerated soft-tissue recovery in preclinical models
  • Gut barrier integrity and ulcer protection
  • Potential nervous system neuroprotection

Safety Profile

Side effects
  • Generally well tolerated in animal studies
  • Injection site irritation
  • Long-term human safety unknown
Contraindications
  • Active malignancy (theoretical angiogenic concern)
  • Pregnancy and lactation
Known interactions
Open interactions explorer →
AnticoagulantsTheoretical synergy via NO modulation — monitor.
VEGF inhibitorsMechanistic opposition; avoid combination.
Storage & handling
  • Unreconstituted vials: store at 2–8 °C long-term; brief room-temperature excursions during shipping are usually acceptable.
  • Reconstituted vials: refrigerate at 2–8 °C, protect from light, use within 30 days.
  • Freezing: acceptable for unreconstituted powder if long-term storage is required; avoid repeated freeze-thaw cycles.
  • Never use a vial that appears cloudy, discoloured or has visible particulates.

Common Mistakes

  • Chasing a bigger dose instead of consistency — BPC-157 outcomes track cumulative exposure, not peak concentration.
  • Skipping baseline bloods, so there is no way to know whether the cycle actually moved a biomarker.
  • Stacking three or four novel compounds at once — you lose the ability to attribute any effect or side effect.
  • Ignoring the training, sleep and nutrition fundamentals that are prerequisites for every peptide protocol.
  • Reusing insulin needles or failing to rotate injection sites — a preventable cause of local reactions and lipohypertrophy.

Evidence Grade — B

Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Below are the primary references used to grade BPC-157. Follow the links for full-text where available and cross-check against the current literature.

Frequently Asked Questions

What is the typical BPC-157 protocol?+

250–500 mcg, 1–2× daily, for 4–6 weeks on, 4 weeks off. Route: Subcutaneous or oral (gut-localized). Timing: Near site of injury or AM/PM fasted. Half-life: ~4 hours (subcutaneous).

How does BPC-157 work?+

Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.

How long before I see results from BPC-157?+

Most users track a full 4–6 weeks on, 4 weeks off cycle before judging response. Subjective changes can appear within 1–3 weeks, but objective biomarker shifts typically need the full cycle plus repeat labs.

Is BPC-157 legal?+

Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.

What are the main side effects of BPC-157?+

Generally well tolerated in animal studies; Injection site irritation; Long-term human safety unknown.

What should I stack with BPC-157?+

Commonly combined with: TB-500, Collagen peptides, Vitamin C. Introduce one compound at a time to preserve attribution.

What biomarkers should I monitor on BPC-157?+

Baseline and post-cycle: full blood count, comprehensive metabolic panel, and category-specific markers for regenerative peptides (see the monitoring section on this page).

Can I run BPC-157 back-to-back?+

Off-cycle periods let receptor sensitivity and endogenous feedback normalise. Continuous dosing without a wash-out typically produces diminishing returns and a poorer safety margin.

References

  1. [1]Stable gastric pentadecapeptide BPC 157 — Current Pharmaceutical Design, 2018

Further reading: Research library → · Protocols →

Comparison vs Alternatives

Open full comparison →All Peptides →
AttributeBPC-157This pageTB-500Retatrutide
EvidenceGrade BGrade BGrade A
CategoryRegenerativeRegenerativeMetabolic
Best forTissue repair, gut integritySoft tissue regenerationTriple GIP/GLP-1/glucagon agonist
Typical dose250–500 mcg2–5 mgTitrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency1–2× daily2× per week loading (4 weeks), then 2–5 mg weekly maintenanceOnce weekly
RouteSubcutaneous or oral (gut-localized)Subcutaneous or intramuscular injectionSubcutaneous injection
Legal statusNot approved by the FDA for human use. Sold as a research chemical in most jurisdictions.WADA-prohibited at all times (S2 class). Research chemical; not approved for human therapeutic use.Investigational; not yet FDA-approved. Currently available only via clinical trials.
ActionCurrent pageView →View →